GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardio Diagnostics Holdings Inc (NAS:CDIO) » Definitions » Cash Conversion Cycle

CDIO (Cardio Diagnostics Holdings) Cash Conversion Cycle : 301.13 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cardio Diagnostics Holdings Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Cardio Diagnostics Holdings's Days Sales Outstanding for the three months ended in Dec. 2024 was 301.13.
Cardio Diagnostics Holdings's Days Inventory for the three months ended in Dec. 2024 was .
Cardio Diagnostics Holdings's Days Payable for the three months ended in Dec. 2024 was .
Therefore, Cardio Diagnostics Holdings's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2024 was 301.13.


Cardio Diagnostics Holdings Cash Conversion Cycle Historical Data

The historical data trend for Cardio Diagnostics Holdings's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardio Diagnostics Holdings Cash Conversion Cycle Chart

Cardio Diagnostics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
- 365.00 365.00 107.35 125.14

Cardio Diagnostics Holdings Quarterly Data
Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 91.25 68.44 153.98 143.39 301.13

Competitive Comparison of Cardio Diagnostics Holdings's Cash Conversion Cycle

For the Biotechnology subindustry, Cardio Diagnostics Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardio Diagnostics Holdings's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's Cash Conversion Cycle falls into.



Cardio Diagnostics Holdings Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Cardio Diagnostics Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=125.14+-
=125.14

Cardio Diagnostics Holdings's Cash Conversion Cycle for the quarter that ended in Dec. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=301.13+-
=301.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardio Diagnostics Holdings  (NAS:CDIO) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Cardio Diagnostics Holdings Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Cardio Diagnostics Holdings's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardio Diagnostics Holdings Business Description

Traded in Other Exchanges
N/A
Address
311 West Superior Street, Suite 444, Chicago, IL, USA, 60654
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.
Executives
Robert Philibert director, 10 percent owner, officer: Chief Medical Officer 400 N. ABERDEEN, SUITE 900, CHICAGO IL 60642
Timur Dogan officer: Chief Technology Officer 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Meeshanthini Dogan director, 10 percent owner, officer: Chief Executive Officer 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Warren Hosseinion director C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Elisa V Luqman officer: Chief Financial Officer 37 HARRISON DRIVE, NORTHPORT NY 11768
Khullani Abdullahi officer: VP of Revenue and Strategy 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Brandon Sim director C/O APOLLO MEDICAL HOLDINGS, INC., 1668 S. GARFIELD AVENUE, 3RD FLOOR, ALHAMBRA CA 91801
James Intrater director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Oded Levy director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Stanley K. Lau director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Bd Holding, Inc. 10 percent owner 15 PROSPECT PLACE, IOWA CITY IA 52246
Jonathan Intrater officer: CEO 223 PALMER STREET, PALMER MA 01069
Allan Liu director 1600 PARKWOOD CIRCLE, STE 200, ATLANTA GA 30339-2119
Loren Mortman director 207 EAST 74TH STREET, APARTMENT 10F, NEW YORK NY 10021
Mana Capital Llc 10 percent owner 8 THE GREEN, SUITE A, DOVER DE 19901

Cardio Diagnostics Holdings Headlines

From GuruFocus